Revolution in GPCR signalling: Opioid receptor heteromers as novel therapeutic targets: IUPHAR Review 10

British Journal of Pharmacology

Volumn 171, Issue 18, 2014, Pages 4155-4176

  Fujita, Wakako ^a   Gomes, Ivone ^a   Devi, Lakshmi A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID RECEPTOR; CATECHOLAMINE RECEPTOR; OPIATE RECEPTOR;

ANIMAL; DRUG DESIGN; HUMAN; METABOLISM; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION;

ANIMALS; DRUG DESIGN; HUMANS; PROTEIN MULTIMERIZATION; RECEPTORS, CANNABINOID; RECEPTORS, CATECHOLAMINE; RECEPTORS, OPIOID; SIGNAL TRANSDUCTION;

EID: 84906834240     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12798     Document Type: Review

References (125)

1. Abdelhamid EE, Takemori AE, (1991). Characteristics of mu and delta opioid binding sites in striatal slices of morphine-tolerant and -dependent mice. Eur J Pharmacol 198: 157-163.
2. Aicher SA, Punnoose A, Goldberg A, (2000a). mu-Opioid receptors often colocalize with the substance P receptor (NK1) in the trigeminal dorsal horn. J Neurosci 20: 4345-4354.
3. Aicher SA, Sharma S, Cheng PY, Liu-Chen LY, Pickel VM, (2000b). Dual ultrastructural localization of mu-opiate receptors and substance P in the dorsal horn. Synapse 36: 12-20.
4. Akgun E, Javed MI, Lunzer MM, Smeester BA, Beitz AJ, Portoghese PS, (2013). Ligands that interact with putative MOR-mGluR5 heteromer in mice with inflammatory pain produce potent antinociception. Proc Natl Acad Sci U S A 110: 11595-11599.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The concise guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
6. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The concise guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol 170: 1797-1867.
7. Ambrose LM, Gallagher SM, Unterwald EM, Van Bockstaele EJ, (2006). Dopamine-D1 and delta-opioid receptors co-exist in rat striatal neurons. Neurosci Lett 399: 191-196.
8. Berg KA, Rowan MP, Gupta A, Sanchez TA, Silva M, Gomes I, et al. (2012). Allosteric interactions between delta and kappa opioid receptors in peripheral sensory neurons. Mol Pharmacol 81: 264-272.
9. Berrendero F, Maldonado R, (2002). Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. Psychopharmacology (Berl) 163: 111-117.
10. Berrendero F, Mendizabal V, Murtra P, Kieffer BL, Maldonado R, (2003). Cannabinoid receptor and WIN 55 212-2-stimulated [35S]-GTPgammaS binding in the brain of mu-, delta- and kappa-opioid receptor knockout mice. Eur J Neurosci 18: 2197-2202.
11. Betoin F, Ardid D, Herbet A, Aumaitre O, Kemeny JL, Duchene-Marullaz P, et al. (1994). Evidence for a central long-lasting antinociceptive effect of vapreotide, an analog of somatostatin, involving an opioidergic mechanism. J Pharmacol Exp Ther 269: 7-14.
12. Bhushan RG, Sharma SK, Xie Z, Daniels DJ, Portoghese PS, (2004). A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers. J Med Chem 47: 2969-2972.
13. Breit A, Lagacé M, Bouvier M, (2004). Hetero-oligomerization between beta2 and beta3-adrenergic receptors generates a beta-adrenergic signaling unit with distinct functional properties. J Biol Chem 279: 28756-28765.
14. Breit A, Gagnidze K, Devi LA, Lagace M, Bouvier M, (2006). Simultaneous activation of the delta opioid receptor (deltaOR)/sensory neuron-specific receptor-4 (SNSR-4) hetero-oligomer by the mixed bivalent agonist bovine adrenal medulla peptide 22 activates SNSR-4 but inhibits deltaOR signaling. Mol Pharmacol 70: 686-696.
15. Bushlin I, Gupta A, Stockton SD Jr, Miller LK, Devi LA, (2012). Dimerization with cannabinoid receptors allosterically modulates delta opioid receptor activity during neuropathic pain. PLoS ONE 7: e49789.
16. Canals M, Marcellino D, Fanelli F, Ciruela F, de Benedetti P, Goldberg SR, et al. (2003). Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem 278: 46741-46749.
17. Chakrabarti S, Liu NJ, Gintzler AR, (2010). Formation of mu-/kappa-opioid receptor heterodimer is sex-dependent and mediates female-specific opioid analgesia. Proc Natl Acad Sci U S A 107: 20115-20119.
18. Charles AC, Mostovskaya N, Asas K, Evans CJ, Dankovich ML, Hales TG, (2003). Coexpression of delta-opioid receptors with micro receptors in GH3 cells changes the functional response to micro agonists from inhibitory to excitatory. Mol Pharmacol 63: 89-95.
19. Chen C, Li J, Bot G, Szabo I, Rogers TJ, Liu-Chen LY, (2004). Heterodimerization and cross-desensitization between the mu-opioid receptor and the chemokine CCR5 receptor. Eur J Pharmacol 483: 175-186.
20. Chuang TK, Killam KF Jr, Chuang LF, Kung HF, Sheng WS, Chao CC, et al. (1995). Mu opioid receptor gene expression in immune cells. Biochem Biophys Res Commun 216: 922-930.
21. Cichewicz DL, (2004). Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 74: 1317-1324.
22. Cussac D, Rauly-Lestienne I, Heusler P, Finana F, Cathala C, Bernois S, et al. (2012). μ-Opioid and 5-HT1A receptors heterodimerize and show signalling crosstalk via G protein and MAP-kinase pathways. Cell Signal 24: 1648-1657.
23. Cvejic S, Devi LA, (1997). Dimerization of the delta opioid receptor: implication for a role in receptor internalization. J Biol Chem 272: 26959-26964.
24. Daniels DJ, Lenard NR, Etienne CL, Law PY, Roerig SC, Portoghese PS, (2005). Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc Natl Acad Sci U S A 102: 19208-19213.
25. Daunais JB, McGinty JF, (1994). Acute and chronic cocaine administration differentially alters striatal opioid and nuclear transcription factor mRNAs. Synapse 18: 35-45.
26. Daval G, Verge D, Basbaum AI, Bourgoin S, Hamon M, (1987). Autoradiographic evidence of serotonin1 binding sites on primary afferent fibres in the dorsal horn of the rat spinal cord. Neurosci Lett 83: 71-76.
27. Decaillot FM, Rozenfeld R, Gupta A, Devi LA, (2008). Cell surface targeting of mu-delta opioid receptor heterodimers by RTP4. Proc Natl Acad Sci U S A 105: 16045-16050.
28. Drasner K, Fields HL, (1988). Synergy between the antinociceptive effects of intrathecal clonidine and systemic morphine in the rat. Pain 32: 309-312.
29. Evans RM, You H, Hameed S, Altier C, Mezghrani A, Bourinet E, et al. (2010). Heterodimerization of ORL1 and opioid receptors and its consequences for N-type calcium channel regulation. J Biol Chem 285: 1032-1040.
30. Fairbanks CA, Posthumus IJ, Kitto KF, Stone LS, Wilcox GL, (2000). Moxonidine, a selective imidazoline/alpha(2) adrenergic receptor agonist, synergizes with morphine and deltorphin II to inhibit substance P-induced behavior in mice. Pain 84: 13-20.
31. Fairbanks CA, Stone LS, Kitto KF, Nguyen HO, Posthumus IJ, Wilcox GL, (2002). alpha(2C)-Adrenergic receptors mediate spinal analgesia and adrenergic-opioid synergy. J Pharmacol Exp Ther 300: 282-290.
32. Fan T, Varghese G, Nguyen T, Tse R, O'Dowd BF, George SR, (2005). A role for the distal carboxyl tails in generating the novel pharmacology and G protein activation profile of mu and delta opioid receptor hetero-oligomers. J Biol Chem 280: 38478-38488.
33. Ferré S, Baler R, Bouvier M, Caron MG, Devi LA, Durroux T, et al. (2009). Building a new conceptual framework for receptor heteromers. Nat Chem Biol 5: 131-134.
34. George SR, Kertesz M, (1987). Met-enkephalin concentrations in striatum respond reciprocally to alterations in dopamine neurotransmission. Peptides 8: 487-492.
35. George SR, Fan T, Xie Z, Tse R, Tam V, Varghese G, et al. (2000). Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. J Biol Chem 275: 26128-26135.
36. Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R, (2002). Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci 22: 1146-1154.
37. Gomes I, Jordan BA, Gupta A, Trapaidze N, Nagy V, Devi LA, (2000). Heterodimerization of mu and delta opioid receptors: a role in opiate synergy. J Neurosci 20: RC110.
38. Gomes I, Gupta A, Filipovska J, Szeto HH, Pintar JE, Devi LA, (2004). A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci U S A 101: 5135-5139.
39. Gomes I, Ijzerman AP, Ye K, Maillet EL, Devi LA, (2011). G protein-coupled receptor heteromerization: a role in allosteric modulation of ligand binding. Mol Pharmacol 79: 1044-1052.
40. Gomes I, Fujita W, Chandrakala MV, Devi LA, (2013a). Disease-specific heteromerization of G-protein-coupled receptors that target drugs of abuse. Prog Mol Biol Transl Sci 117: 207-265.
41. Gomes I, Fujita W, Gupta A, Saldanha AS, Negri A, Pinello CE, et al. (2013b). Identification of a mu-delta opioid receptor heteromer-biased agonist with antinociceptive activity. Proc Natl Acad Sci U S A 110: 12072-12077.
42. Grazzini E, Puma C, Roy MO, Yu XH, O'Donnell D, Schmidt R, et al. (2004). Sensory neuron-specific receptor activation elicits central and peripheral nociceptive effects in rats. Proc Natl Acad Sci U S A 101: 7175-7180.
43. Guo XH, Fairbanks CA, Stone LS, Loh HH, (2003). DPDPE-UK14,304 synergy is retained in mu opioid receptor knockout mice. Pain 104: 209-217.
44. Gupta A, Mulder J, Gomes I, Rozenfeld R, Bushlin I, Ong E, et al. (2010). Increased abundance of opioid receptor heteromers after chronic morphine administration. Sci Signal 3: ra54.
45. Harvey JH, Long DH, England PM, Whistler JL, (2012). Tuned-affinity bivalent ligands for the characterization of opioid receptor heteromers. ACS Med Chem Lett 3: 640-644.
46. Hasbi A, Nguyen T, Fan T, Cheng R, Rashid A, Alijaniaram M, et al. (2007). Trafficking of preassembled opioid mu-delta heterooligomer-Gz signaling complexes to the plasma membrane: coregulation by agonists. Biochemistry 46: 12997-13009.
47. He L, Fong J, von Zastrow M, Whistler JL, (2002). Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell 108: 271-282.
48. He SQ, Zhang ZN, Guan JS, Liu HR, Zhao B, Wang HB, et al. (2011). Facilitation of mu-opioid receptor activity by preventing delta-opioid receptor-mediated codegradation. Neuron 69: 120-131.
49. Hojo M, Sudo Y, Ando Y, Minami K, Takada M, Matsubara T, et al. (2008). mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. J Pharmacol Sci 108: 308-319.
50. Huang MH, Wang HQ, Roeske WR, Birnbaum Y, Wu Y, Yang NP, et al. (2007). Mediating delta-opioid-initiated heart protection via the beta2-adrenergic receptor: role of the intrinsic cardiac adrenergic cell. Am J Physiol Heart Circ Physiol 293: H376-H384.
51. Ito S, Mori T, Sawaguchi T, (2006). Differential effects of micro-opioid, delta-opioid and kappa-opioid receptor agonists on dopamine receptor agonist-induced climbing behavior in mice. Behav Pharmacol 17: 691-701.
52. Jordan BA, Devi LA, (1999). G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399: 697-700.
53. Jordan BA, Trapaidze N, Gomes I, Nivarthi R, Devi LA, (2001). Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation. Proc Natl Acad Sci U S A 98: 343-348.
54. Jordan BA, Gomes I, Rios C, Filipovska J, Devi LA, (2003). Functional interactions between mu opioid and alpha 2A-adrenergic receptors. Mol Pharmacol 64: 1317-1324.
55. King M, Chang A, Pasternak GW, (1998). Functional blockade of opioid analgesia by orphanin FQ/nociceptin. Biochem Pharmacol 55: 1537-1540.
56. Kishimoto K, Koyama S, Akaike N, (2001). Synergistic mu-opioid and 5-HT1A presynaptic inhibition of GABA release in rat periaqueductal gray neurons. Neuropharmacology 41: 529-538.
57. Largent-Milnes TM, Brookshire SW, Skinner DP Jr, Hanlon KE, Giuvelis D, Yamamoto T, et al. (2013). Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects. J Pharmacol Exp Ther 347: 7-19.
58. Law PY, Erickson-Herbrandson LJ, Zha QQ, Solberg J, Chu J, Sarre A, et al. (2005). Heterodimerization of mu- and delta-opioid receptors occurs at the cell surface only and requires receptor-G protein interactions. J Biol Chem 280: 11152-11164.
59. Le Naour M, Akgun E, Yekkirala A, Lunzer MM, Powers MD, Kalyuzhny AE, et al. (2013). Bivalent ligands that target mu opioid (MOP) and cannabinoid1 (CB) receptors are potent analgesics devoid of tolerance. J Med Chem 56: 5505-5513.
60. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, et al. (1999). Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283: 401-404.
61. Lembo PM, Grazzini E, Groblewski T, O'Donnell D, Roy MO, Zhang J, et al. (2002). Proenkephalin A gene products activate a new family of sensory neuron-specific GPCRs. Nat Neurosci 5: 201-209.
62. Lenard NR, Daniels DJ, Portoghese PS, Roerig SC, (2007). Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores. Eur J Pharmacol 566: 75-82.
63. Li Y, Chen J, Bai B, Du H, Liu Y, Liu H, (2012). Heterodimerization of human apelin and kappa opioid receptors: roles in signal transduction. Cell Signal 24: 991-1001.
64. Liu XY, Liu ZC, Sun YG, Ross M, Kim S, Tsai FF, et al. (2011). Unidirectional cross-activation of GRPR by MOR1D uncouples itch and analgesia induced by opioids. Cell 147: 447-458.
65. Lutz PE, Pradhan AA, Goeldner C, Kieffer BL, (2011). Sequential and opposing alterations of 5-HT(1A) receptor function during withdrawal from chronic morphine. Eur Neuropsychopharmacol 21: 835-840.
66. Majumdar S, Grinnell S, Le Rouzic V, Burgman M, Polikar L, Ansonoff M, et al. (2011). Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects. Proc Natl Acad Sci U S A 108: 19778-19783.
67. Manglik A, Kruse AC, Kobilka TS, Thian FS, Mathiesen JM, Sunahara RK, et al. (2012). Crystal structure of the μ-opioid receptor bound to a morphinan antagonist. Nature 485: 321-326.
68. Metcalf MD, Yekkirala AS, Powers MD, Kitto KF, Fairbanks CA, Wilcox GL, et al. (2012). The delta opioid receptor agonist SNC80 selectively activates heteromeric mu-delta opioid receptors. ACS Chem Neurosci 3: 505-509.
69. Milan-Lobo L, Whistler JL, (2011). Heteromerization of the mu- and delta-opioid receptors produces ligand-biased antagonism and alters mu-receptor trafficking. J Pharmacol Exp Ther 337: 868-875.
70. Miyagi T, Chuang LF, Doi RH, Carlos MP, Torres JV, Chuang RY, (2000). Morphine induces gene expression of CCR5 in human CEM x174 lymphocytes. J Biol Chem 275: 31305-31310.
71. Nayebi AR, Charkhpour M, (2006). Role of 5-HT(1A) and 5-HT(2) receptors of dorsal and median raphe nucleus in tolerance to morphine analgesia in rats. Pharmacol Biochem Behav 83: 203-207.
72. Ossipov MH, Lopez Y, Bian D, Nichols ML, Porreca F, (1997). Synergistic antinociceptive interactions of morphine and clonidine in rats with nerve-ligation injury. Anesthesiology 86: 196-204.
73. Overland AC, Kitto KF, Chabot-Dore AJ, Rothwell PE, Fairbanks CA, Stone LS, et al. (2009). Protein kinase C mediates the synergistic interaction between agonists acting at alpha(2)-adrenergic and delta-opioid receptors in spinal cord. J Neurosci 29: 13264-13273.
74. Pan YX, Bolan E, Pasternak GW, (2002). Dimerization of morphine and orphanin FQ/nociceptin receptors: generation of a novel opioid receptor subtype. Biochem Biophys Res Commun 297: 659-663.
75. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucleic Acids Res 42 (Database Issue): D1098-D1106.
76. Pello OM, Martinez-Munoz L, Parrillas V, Serrano A, Rodriguez-Frade JM, Toro MJ, et al. (2008). Ligand stabilization of CXCR4/delta-opioid receptor heterodimers reveals a mechanism for immune response regulation. Eur J Immunol 38: 537-549.
77. Pepe S, Xiao RP, Hohl C, Altschuld R, Lakatta EG, (1997). Cross talk' between opioid peptide and adrenergic receptor signaling in isolated rat heart. Circulation 95: 2122-2129.
78. Pfeiffer M, Koch T, Schroder H, Laugsch M, Hollt V, Schulz S, (2002). Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J Biol Chem 277: 19762-19772.
79. Pfeiffer M, Kirscht S, Stumm R, Koch T, Wu D, Laugsch M, et al. (2003). Heterodimerization of substance P and mu-opioid receptors regulates receptor trafficking and resensitization. J Biol Chem 278: 51630-51637.
80. Pompeiano M, Palacios JM, Mengod G, (1992). Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding. J Neurosci 12: 440-453.
81. Ramsay D, Kellett E, McVey M, Rees S, Milligan G, (2002). Homo- and hetero-oligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences. Biochem J 365: 429-440.
82. Reaux A, De Mota N, Skultetyova I, Lenkei Z, El Messari S, Gallatz K, et al. (2001). Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain. J Neurochem 77: 1085-1096.
83. Riedl MS, Schnell SA, Overland AC, Chabot-Dore AJ, Taylor AM, Ribeiro-Da-Silva A, et al. (2009). Coexpression of alpha(2A)-adrenergic and delta-opioid receptors in substance P-containing terminals in rat dorsal horn. J Comp Neurol 514: 674-674.
84. Rios C, Gomes I, Devi LA, (2004). Interactions between delta opioid receptors and alpha-adrenoceptors. Clin Exp Pharmacol Physiol 31: 833-836.
85. Rios C, Gomes I, Devi LA, (2006). mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 148: 387-395.
86. Rives ML, Rossillo M, Liu-Chen LY, Javitch JA, (2012). 6â€-guanidinonaltrindole (6â€-GNTI) is a G protein-biased κ-opioid receptor agonist that inhibits arrestin recruitment. J Biol Chem 287: 27050-27054.
87. Rizzi A, Bigoni R, Marzola G, Guerrini R, Salvadori S, Regoli D, et al. (2000). The nociceptin/orphanin FQ receptor antagonist, [Nphe1]NC(1-13)NH2, potentiates morphine analgesia. Neuroreport 11: 2369-2372.
88. Rothman RB, Bowen WD, Herkenham M, Jacobson AE, Rice KC, Pert CB, (1985). A quantitative study of [3H]D-Ala2-D-Leu5-enkephalin binding to rat brain membranes. Evidence that oxymorphone is a noncompetitive inhibitor of the lower affinity delta-binding site. Mol Pharmacol 27: 399-409.
89. Rothman RB, Long JB, Bykov V, Jacobson AE, Rice KC, Holaday JW, (1988). beta-FNA binds irreversibly to the opiate receptor complex: in vivo and in vitro evidence. J Pharmacol Exp Ther 247: 405-416.
90. Rozenfeld R, Devi LA, (2007). Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers. FASEB J 21: 2455-2465.
91. Rozenfeld R, Bushlin I, Gomes I, Tzavaras N, Gupta A, Neves S, et al. (2012). Receptor heteromerization expands the repertoire of cannabinoid signaling in rodent neurons. PLoS ONE 7: e29239.
92. Sastre-Coll A, Esteban S, Garcia-Sevilla JA, (2002). Supersensitivity of 5-HT1A autoreceptors and alpha2-adrenoceptors regulating monoamine synthesis in the brain of morphine-dependent rats. Naunyn Schmiedebergs Arch Pharmacol 365: 210-219.
93. Schroder H, Wu DF, Seifert A, Rankovic M, Schulz S, Hollt V, et al. (2009). Allosteric modulation of metabotropic glutamate receptor 5 affects phosphorylation, internalization, and desensitization of the micro-opioid receptor. Neuropharmacology 56: 768-778.
94. Schulz S, Schreff M, Schmidt H, Handel M, Przewlocki R, Höllt V, (1998). Immunocytochemical localization of somatostatin receptor sst2A in the rat spinal cord and dorsal root ganglia. Eur J Neurosci 10: 3700-3708.
95. Schuster DJ, Kitto KF, Overland AC, Messing RO, Stone LS, Fairbanks CA, et al. (2013). Protein kinase Cε is required for spinal analgesic synergy between delta opioid and alpha-2A adrenergic receptor agonist pairs. J Neurosci 33: 13538-13546.
96. Shapira M, Gafni M, Sarne Y, (1998). Independence of, and interactions between, cannabinoid and opioid signal transduction pathways in N18TG2 cells. Brain Res 806: 26-35.
97. Sherman TG, Civelli O, Douglass J, Herbert E, Watson SJ, (1986). Coordinate expression of hypothalamic pro-dynorphin and pro-vasopressin mRNAs with osmotic stimulation. Neuroendocrinology 44: 222-228.
98. Song C, Rahim RT, Davey PC, Bednar F, Bardi G, Zhang L, et al. (2011). Protein kinase Czeta mediates micro-opioid receptor-induced cross- desensitization of chemokine receptor CCR5. J Biol Chem 286: 20354-20365.
99. Stone LS, MacMillan LB, Kitto KF, Limbird LE, Wilcox GL, (1997). The alpha2a adrenergic receptor subtype mediates spinal analgesia evoked by alpha2 agonists and is necessary for spinal adrenergic-opioid synergy. J Neurosci 17: 7157-7165.
100. Suzuki S, Chuang LF, Yau P, Doi RH, Chuang RY, (2002). Interactions of opioid and chemokine receptors: oligomerization of mu, kappa, and delta with CCR5 on immune cells. Exp Cell Res 280: 192-200.
101. Tai KK, Jin WQ, Chan TK, Wong TM, (1991). Characterization of [3H]U69593 binding sites in the rat heart by receptor binding assays. J Mol Cell Cardiol 23: 1297-1302.
102. Tan M, Walwyn WM, Evans CJ, Xie CW, (2009). p38 MAPK and beta-arrestin 2 mediate functional interactions between endogenous micro-opioid and alpha2A-adrenergic receptors in neurons. J Biol Chem 284: 6270-6281.
103. Terrilon S, Durroux T, Mouillac B, Breit A, Ayoub MA, Taulan M, et al. (2003). Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. Mol Endocrinol 17: 677-691.
104. Tsushima H, Mori M, Matsuda T, (1993). Microinjection of dynorphin into the supraoptic and paraventricular nuclei produces antidiuretic effects through vasopressin release. Jpn J Pharmacol 63: 461-468.
105. Unterwald EM, Cuntapay M, (2000). Dopamine-opioid interactions in the rat striatum: a modulatory role for dopamine D1 receptors in delta opioid receptor-mediated signal transduction. Neuropharmacology 39: 372-381.
106. Uriguen L, Berrendero F, Ledent C, Maldonado R, Manzanares J, (2005). Kappa- and delta-opioid receptor functional activities are increased in the caudate putamen of cannabinoid CB1 receptor knockout mice. Eur J Neurosci 22: 2106-2110.
107. Vardanyan R, Kumirov VK, Nichol GS, Davis P, Liktor-Busa E, Rankin D, et al. (2011). Synthesis and biological evaluation of new opioid agonist and neurokinin-1 antagonist bivalent ligands. Bioorg Med Chem 19: 6135-6142.
108. Vaught JL, Takemori AE, (1979a). Differential effects of leucine and methionine enkephalin on morphine-induced analgesia, acute tolerance and dependence. J Pharmacol Exp Ther 208: 86-90.
109. Vaught JL, Takemori AE, (1979b). A further characterization of the differential effects of leucine enkephalin, methionine enkephalin and their analogs on morphine-induced analgesia. J Pharmacol Exp Ther 211: 280-283.
110. Ventura C, Bastagli L, Bernardi P, Caldarera CM, Guarnieri C, (1989). Opioid receptors in rat cardiac sarcolemma: effect of phenylephrine and isoproterenol. Biochim Biophys Acta 987: 69-74.
111. Vilardaga JP, Nikolaev VO, Lorenz K, Ferrandon S, Zhuang Z, Lohse MJ, (2008). Conformational cross-talk between alpha2A-adrenergic and mu-opioid receptors controls cell signaling. Nat Chem Biol 4: 126-131.
112. Waldhoer M, Fong J, Jones RM, Lunzer MM, Sharma SK, Kostenis E, et al. (2005). A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc Natl Acad Sci U S A 102: 9050-9055.
113. Wang D, Sun X, Bohn LM, Sadee W, (2005a). Opioid receptor homo- and heterodimerization in living cells by quantitative bioluminescence resonance energy transfer. Mol Pharmacol 67: 2173-2184.
114. Wang HL, Hsu CY, Huang PC, Kuo YL, Li AH, Yeh TH, et al. (2005b). Heterodimerization of opioid receptor-like 1 and mu-opioid receptors impairs the potency of micro receptor agonist. J Neurochem 92: 1285-1294.
115. Wang QP, Ochiai H, Guan JL, Nakai Y, (1998). Ultrastructural localization of mu-1 opioid receptor in the dorsal raphe nucleus of the rat. Synapse 29: 240-247.
116. Xiao RP, Pepe S, Spurgeon HA, Capogrossi MC, Lakatta EG, (1997). Opioid peptide receptor stimulation reverses beta-adrenergic effects in rat heart cells. Am J Physiol 272: H797-H805.
117. Yamamoto T, Nair P, Davis P, Ma SW, Navratilova E, Moye S, et al. (2007). Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokinin-1 receptor antagonists. J Med Chem 50: 2779-2786.
118. Yekkirala AS, Lunzer MM, McCurdy CR, Powers MD, Kalyuzhny AE, Roerig SC, et al. (2011). N-naphthoyl-beta-naltrexamine (NNTA), a highly selective and potent activator of mu/kappa-opioid heteromers. Proc Natl Acad Sci U S A 108: 5098-5103.
119. Yekkirala AS, Kalyuzhny AE, Portoghese PS, (2013). An Immunocytochemical-derived correlate for evaluating the bridging of heteromeric mu-delta opioid protomers by bivalent ligands. ACS Chem Biol 8: 1412-1416.
120. Yuan Y, Arnatt CK, Li G, Haney KM, Ding D, Jacob JC, et al. (2012). Design and synthesis of a bivalent ligand to explore the putative heterodimerization of the mu opioid receptor and the chemokine receptor CCR5. Org Biomol Chem 10: 2633-2646.
121. Yuan Y, Arnatt CK, El-Hage N, Dever SM, Jacob JC, Selley DE, et al. (2013). A bivalent ligand targeting the putative mu opioid receptor and chemokine receptor CCR5 heterodimers: binding affinity versus functional activities. Med Chem Comm 4: 847-851.
122. Zhang YQ, Limbird LE, (2004). Hetero-oligomers of alpha2A-adrenergic and mu-opioid receptors do not lead to transactivation of G-proteins or altered endocytosis profiles. Biochem Soc Trans 32: 856-860.
123. Zhang YQ, Gao X, Huang YL, Wu GC, (2000). Expression of 5-HT1A receptor mRNA in rat dorsal raphe nucleus and ventrolateral periaqueductal gray neurons after peripheral inflammation. Neuroreport 11: 3361-3365.
124. Zhu Y, King MA, Schuller AG, Nitsche JF, Reidl M, Elde RP, et al. (1999). Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron 24: 243-252.
125. Zieglgänsberger W, French ED, Mercuri N, Pelayo F, Williams JT, (1982). Multiple opiate receptors on neurons of the mammalian central nervous system. In vivo and in vitro studies. Life Sci 31: 2343-2346.